Inside J&J's Next Blockbuster Drug
By BloombergJ&J's CFO Joseph Wolk joined Bloomberg Open Interest to talk about why its newly launched psoriasis pill could become one of its biggest drugs ever, already reaching 1,500 patients in just days. He explains how the company is avoiding risky mega-deals thanks to a strong pipeline, while confidently raising guidance and betting on long-term double-digit growth.